Description

A study by StrategyHelix indicates that the global nanomaterials in personalized medicine market is expected to increase by US$ 229.3 billion from 2022 to 2028, garnering a CAGR of 9.8% during the forecast period.

The report provides up-to-date market size data for period 2018-2021 and forecast to 2028 covering key market aspects like sales value for nanomaterials in personalized medicine. The global nanomaterials in personalized medicine market is segmented on the basis of product, and region. Based on product, the global nanomaterials in personalized medicine market is categorized into gold nanoparticles, liposomes, monoclonal antibodies, nanocrystals, proteins, quantum dots. The proteins segment captured the largest share of the market in 2021. In terms of geography, the global nanomaterials in personalized medicine market has been segmented into Asia Pacific, Europe, North America, Rest of the World (RoW).

The global nanomaterials in personalized medicine market is highly competitive. The key players in the nanomaterials in personalized medicine market include Abraxis BioScience Inc., Bristol-Myers Squibb Company (BMS), Camurus AB, Eisai Co. Ltd., Johnson & Johnson, Merck & Co. Inc., NanoCarrier Co. Ltd., Novartis AG. Competitive landscape gives a description of the competitive nature of the global nanomaterials in personalized medicine market and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.

The report is an invaluable resource for companies and organizations active in this industry. It provides a cohesive picture of the nanomaterials in personalized medicine market to help drive informed decision making for industry executives, policy makers, academic, and analysts.

Report Scope

Product: gold nanoparticles, liposomes, monoclonal antibodies, nanocrystals, proteins, quantum dots
Region: Asia Pacific, Europe, North America, Rest of the World (RoW)
Years considered: this report covers the period 2018 to 2028
Company mentioned: Abraxis BioScience Inc., Bristol-Myers Squibb Company (BMS), Camurus AB, Eisai Co. Ltd., Johnson & Johnson, Merck & Co. Inc., NanoCarrier Co. Ltd., Novartis AG

Key Benefits for Stakeholders

– Get a comprehensive picture of the global nanomaterials in personalized medicine market
– Pinpoint growth sectors and trends for investment

Table of Contents

Part 1. Introduction
– Scope of the study
– Study period
– Geographical scope
– Research methodology
Part 2. Nanomaterials in personalized medicine market overview
Part 3. Market breakdown by product
– Gold nanoparticles
– Liposomes
– Monoclonal antibodies
– Nanocrystals
– Proteins
– Quantum dots
Part 4. Market breakdown by region
– Asia Pacific
– Europe
– North America
– Rest of the World (RoW)
Part 5. Key companies
– Abraxis BioScience, Inc.
– Bristol-Myers Squibb Company (BMS)
– Camurus AB
– Eisai Co., Ltd.
– Johnson & Johnson
– Merck & Co., Inc.
– NanoCarrier Co., Ltd.
– Novartis AG
About StrategyHelix
Disclaimer